Timothy S. Olson, MD, PhD

Timothy S. Olson, MD, PhD, focuses on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure.

Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP

  • Background

    My clinical efforts focus on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure. Through my combined clinical activities in the Bone Marrow Failure Center within the Division of Hematology and the Blood and Marrow Transplant Section within the Division of Oncology, my goal is to facilitate outstanding care for patients with inherited bone marrow failure and acquired aplastic anemia during their transition from diagnostic evaluation to treatment through HSCT.

    In coordination with these clinical efforts, my clinical research program seeks to retrospectively and prospectively assess outcomes for patients undergoing HSCT due to inherited and acquired bone marrow failure syndromes, defined and stratified by distinct cytogenetic abnormalities. Our ultimate goal is to develop targeted clinical trials which will serve to define optimal treatment strategies for patients with distinct genetic and immunologic etiologies of bone marrow failure.

    The goal of my laboratory research program is to improve HSCT outcomes by identifying methods to decrease the incidence of graft failure following HSCT, which is a particularly critical challenge in the setting of transplant for non-malignant conditions such as bone marrow failure. We are specifically examining methods to enhance donor hematopoietic stem cell (HSC) engraftment efficiency following HSCT through enhancement of the functions of specialized areas of the bone marrow microenvironment, known hematopoietic stem cell niches. We are currently testing therapeutic strategies that can be applied to enhance niche activity and receptivity for donor stem cells, which could be utilized to improve donor engraftment efficiency following clinical HSCT.
     

  • Education and Training

    Medical School

    MD - University of Virginia School of Medicine, Charlottesville, VA

    Residency

    Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

    Fellowship

    Pediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA

    Board Certification

    Pediatrics

    Graduate Degree

    PhD in Molecular Physiology - University of Virginia, Charlottesville, VA

  • Titles and Academic Titles

    Attending Physician</br>Instructor in Pediatric Hematology-Oncology</br>Clinical associate in Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Centers and Programs
  • Publications

    Posters and Presentations

    2012

    TS Olson, A Caselli, S Otsuru, T Hofmann, and EM Horwitz. Enhancement of hematopoietic stem cell engraftment efficiency through upregulation of host megakaryocyte-driven endosteal stem cell niche expansion following radioablative conditioning [oral presentation]. The Future of Stem Cell Transplantation Meeting; 2012 Jan;  Atlanta, GA.

    2011

    TS Olson, A Caselli, S Otsuru, T Hofmann, and EM Horwitz. Host-derived megakaryocytes enable efficient hematopoietic stem cell engraftment following radioablation through facilitation of osteoblastic stem cell niche expansion [oral presentation]. American Society of Pediatric Hematology/Oncology 24th Annual Meeting; 2011 Apr 13-16; Baltimore, MD.

    2010

    TS Olson, A Caselli, S Otsuru, T Hofmann, and EM Horwitz. Novel role for host-derived megakaryocytes in facilitating stem cell engraftment through enhancement of osteoblastic niche restoration following radioablation [oral presentation].  American Society of Hematology 52nd Annual Meeting; 2010 Dec 4-7; Orlando, FL.